Case Report
Copyright ©The Author(s) 2022.
World J Clin Cases. May 6, 2022; 10(13): 4137-4144
Published online May 6, 2022. doi: 10.12998/wjcc.v10.i13.4137
Figure 2
Figure 2 Fluorine-18-fluorodeoxyglucose-positron emission tomography/computed tomography fusion images. A and B: Fluorine-18-fluorodeoxyglucose (18F-FDG) uptake in the subclavian artery before immunosuppressive treatment (A) and after 6 mo of treatment (B) (SUVmax A > B); C and D: 18F-FDG uptake in the thoracic aorta before immunosuppressive treatment (C) and after 6 mo of treatment (D) (SUVmax C > D); E and F: 18F-FDG uptake in the aorta abdominalis before immunosuppressive treatment (E) and after 6 mo of treatment (F) (SUVmax E > F) by 18F-FDG-positron emission tomography/computed tomography fusion images.